Die globalen Wachstumsmöglichkeiten für FinTechs erscheinen enorm. Erfahren Sie, wie Sie als Anleger am FinTech-Markt partizipieren könnten.-w-
29.07.2021 23:30

Global $57.4 Billion Cell And Gene Therapy Manufacturing Market to 2028 - Rising Pressure on Drug Developers/Manufacturers to Meet the Growing Market Demand


DUBLIN, July 29, 2021 /PRNewswire/ -- The "Cell And Gene Therapy Manufacturing Market Size, Share & Trends Analysis Report by Therapy Type, by Scale (R&D, Commercial), by Mode, by Workflow (Vector Production, Cell Banking), by Region, and Segment Forecasts, 2021 - 2028" report has been added to ResearchAndMarkets.com's offering.

Research and Markets Logo

The global cell and gene therapy manufacturing market size is expected to reach USD 57.4 billion by 2028.

The market is estimated to expand at a CAGR of 20.3% from 2021 to 2028. An exponential rise in clinical pipeline coupled with a rising number of regulatory approvals for advanced therapies has majorly driven the market.

Considering promising growth opportunities in contract development of cellular and gene-modified therapies, market participants are making focused efforts to boost their market presence.

Also, bio manufacturers are signing strategic alliances with contract manufacturers to accelerate the R&D of their candidate programs. Rising demand for CMOs/CDMOs services has led to the entry of several new players as well as expansion of product development capabilities, thereby positively impacting market revenue.

Several novel methods are being introduced to advance cell and gene therapy manufacturing. For instance, the manufacturers are exploring the potential of single-use technology in production workflows.

This technique is gaining increasing attention in this arena to speed the development process while reducing the overall cost and production timeline. Such technological advancements in space are anticipated to bolster market growth in the coming years.

Cell And Gene Therapy Manufacturing Market Report Highlights

  • The cell therapy manufacturing segment dominated the market in 2020 in terms of revenue
  • A high number of ongoing clinical trials of cell therapies to address the robust need for effective treatment against COVID-19 infection has resulted in segment growth
  • A high number of candidate molecules in the pre-commercial scale stage has contributed to the largest revenue share of the segment in 2020
  • On the other hand, the recent success of CAR-T therapies supplements the growth of the commercial-scale manufacturing segment
  • The contract manufacturing segment is expected to witness lucrative growth during the forecast period as a substantial number of bio manufacturers are turning to CMOs for efficient and rapid product development
  • Ongoing pandemic has accelerated the global investments in the R&D of viral vector-based vaccines, creating lucrative opportunities in the vector production segment
  • North America dominated the market in terms of revenue in 2020 owing to the strong research as well as a commercial base for cell and gene therapy products in the U.S.
  • U.S. is leading the CAR-T and gene therapy space with the highest number of approved products, thus positively influencing market growth in the region
  • Asia Pacific is anticipated to grow at the fastest rate throughout the forecast period
  • Constantly evolving viral vector production and CDMO landscapes through plant expansions and new sites are spurring the market in this region
  • The key players are engaged in collaboration with biopharma developers to support their product development process

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Market Variables, Trends & Scope
3.1 Market Segmentation
3.2 Parent Market Lineage
3.3 Ancillary Market Lineage
3.4 Market Dynamics
3.4.1 Market Drivers Analysis Growing Pipeline Of Cell and Gene Therapy Supportive Regulatory Bodies Increase In Investment By Government and Private Players
3.4.2 Market Restraint Analysis Technological Challenges Associated With Manufacturing High Cost Of Manufacturing
3.4.3 Market Opportunity Analysis Rising Pressure On Drug Developers/Manufacturers To Meet The Growing Market Demand Expansion In Potential Markets Such As Asia Pacific and Latin America
3.4.4 Market Challenge Analysis Lack Of Manufacturing Capacity
3.5 Swot Analysis; By Factor (Political & Legal, Economic and Technological)
3.6 Porter's Five Forces Analysis
3.7 Major Deals and Strategic Alliances Analysis
3.8 Covid-19 Impact Analysis

Chapter 4 Competitive Analysis
4.1 Recent Developments and Impact Analysis By Key Market Participants
4.2 Company Mapping, By Location, Purpose, Scale Of Operation, Source Of Cell, Regulatory Compliant
4.3 List Of Potential End Users
4.4 List Of Emerging Players
4.5 Market Differentiators
4.6 Competitive Dashboard Analysis
4.7 Regional Network Map

Chapter 5 Therapy Type Business Analysis
5.1 Cell and Gene Therapy Manufacturing Market: Therapy Type Movement Analysis
5.2 Cell Therapy Manufacturing
5.2.2 Stem Cell Therapy
5.2.3 Non-Stem Cell Therapy
5.3 Gene Therapy Manufacturing

Chapter 6 Scale Business Analysis
6.1 Cell and Gene Therapy Manufacturing Market: Scale Movement Analysis
6.2 Pre-Commercial/R&D Scale Manufacturing
6.3 Commercial Scale Manufacturing

Chapter 7 Mode Business Analysis
7.1 Cell and Gene Therapy Manufacturing Market: Mode Movement Analysis
7.2 Contract Manufacturing
7.3 In-House Manufacturing

Chapter 8 Workflow Business Analysis
8.1 Cell and Gene Therapy Manufacturing Market: Workflow Movement Analysis
8.2 Cell Processing
8.3 Cell Banking
8.4 Process Development
8.5 Fill and Finish Operations
8.6 Analytical and Quality Testing
8.7 Raw Material Testing
8.8 Vector Production

Chapter 9 Regional Business Analysis
9.1 Cell and Gene Therapy Manufacturing Market: Regional Movement Analysis

Chapter 10 Company Profiles

  • Thermofisher Scientific
  • Merck Kgaa.
  • Lonza
  • Catalent Inc.
  • Takara Bio Inc.
  • F.Hoffmann-La Roche Ltd
  • Wuxi Advanced Therapies
  • Samsung Biologics
  • Boehringer Ingelheim International Gmbh
  • Novartis Ag
  • Hitachi Chemical Co Ltd.
  • Cellular Therapeutics.
  • Miltenyi Biotech.
  • Bluebird Bio Inc.

For more information about this report visit https://www.researchandmarkets.com/r/yqyeht

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1904
Fax (outside U.S.): +353-1-481-1716

Cision View original content:https://www.prnewswire.com/news-releases/global-57-4-billion-cell-and-gene-therapy-manufacturing-market-to-2028---rising-pressure-on-drug-developersmanufacturers-to-meet-the-growing-market-demand-301344484.html

SOURCE Research and Markets

Börse Stuttgart Anlegerclub

Heute im Fokus

Vor Fed-Entscheid: Wall Street fester -- DAX in Grün -- Airbus bestätigt erhöhte Produktionsziele -- Babbel bläst Börsengang ab -- FedEx, Evergrande, Lufthansa, VW, Vonovia im Fokus

USA wollen noch mehr Impfstoff von BioNTech/Pfizer spenden. Schnelleres Ende im Untreue-Prozess gegen VW-Manager möglich. EDF führt Gespräche mit GE über Atomkraft-Geschäfte. Allianz stellt Untersuchung zu Elektroauto-Risiken vor. VERBIO sieht Gewinnziel unter Vorjahresniveau. Bayer steigt 2022 in das Geschäft mit Bio-Gemüsesaatgut ein. Flutter vergleicht sich mit Kentucky auf Millionenzahlung.


Würden Sie es für richtig halten, wenn Gastronomie und Veranstaltungen nur noch Geimpften und Genesenen offen stehen?

finanzen.net zero
finanzen.net zero



Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.
Zur klassischen Ansicht wechseln